[{"indications": "Indications\u00a0see\r\nnotes above", "name": "ETHINYLESTRADIOL - ETHINYLESTRADIOL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.1 Female sex hormones", "6.4.1.1 Oestrogens and HRT", "Ethinylestradiol", "ETHINYLESTRADIOL"], "cautions": "Cautions\u00a0cardiovascular disease (sodium retention with oedema, thromboembolism); see also under Combined Hormonal Contraceptives (section 7.3.1) and under Oestrogens for HRT ", "side-effects": "Side-effects\u00a0feminising effects in men; see also under Combined Hormonal Contraceptives (section 7.3.1) and under Oestrogens for HRT", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4334.htm", "doses": ["Menopausal symptoms and osteoporosis prophylaxis, (with\r\nprogestogen for 12\u201314 days per cycle in women with intact uterus),\r\n10\u201350\u00a0micrograms daily for 21 days, repeated after 7-day tablet-free\r\nperiod", "Female hypogonadism, 10\u201350\u00a0micrograms daily, usually on cyclical\r\nbasis; initial oestrogen therapy should be followed by combined oestrogen\r\nand progestogen therapy", "Menstrual disorders, 20\u201350\u00a0micrograms daily from day 5 to 25\r\nof each cycle, with progestogen added either throughout the cycle\r\nor from day 15 to 25"], "pregnancy": "Pregnancy\u00a0see Combined Hormonal Contraceptives, section 7.3.1"}, {"indications": "Indications\u00a0\n(From 8.3.1 Oestrogens: British National Formulary)\n8.3.1 Oestrogens; other indications (%s\n(From Ethinylestradiol: British National Formulary)\nEthinylestradiol)", "name": "ETHINYLESTRADIOL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.1 Oestrogens", "ETHINYLESTRADIOL"], "cautions": "Cautions\u00a0see section 6.4.1.1; interactions: Appendix 1 (oestrogens)", "side-effects": "Side-effects\u00a0see section 6.4.1.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/100122.htm", "doses": ["Prostate cancer (palliative), 0.15\u20131.5\u00a0mg daily"]}, {"indications": "Indications\u00a0\n(From 8.3.1 Oestrogens: British National Formulary)\n8.3.1 Oestrogens; other indications (%s\n(From Ethinylestradiol: British National Formulary)\nEthinylestradiol)", "name": "ETHINYLESTRADIOL - OESTROGENS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.1 Oestrogens", "ETHINYLESTRADIOL"], "cautions": "Cautions\u00a0see section 6.4.1.1; interactions: Appendix 1 (oestrogens)", "side-effects": "Side-effects\u00a0see section 6.4.1.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/100122.htm", "doses": ["Prostate cancer (palliative), 0.15\u20131.5\u00a0mg daily"]}]